Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
0.00 (0.00%)
Pre-market: 74.04 +1.42 (1.96%)
Feb 10, 8:20AM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 71.90 - 106.84
Open     -
Vol / Avg. 3,328.00/2.46M
Mkt cap 189.56B
P/E 25.26
Div/yield 2.76/3.67
EPS 2.88
Shares 2.37B
Beta 0.64
Inst. own 10%
Apr 21, 2016
Q1 2016 Novartis AG Earnings Release Add to calendar
Mar 15, 2016
Novartis AG at Exane Bnp Healthcare Conference Add to calendar
Mar 2, 2016
Novartis AG at Credit Suisse One-on-One Healthcare Conference Add to calendar
Feb 23, 2016
Novartis AG Annual Shareholders Meeting - 4:00AM EST - Add to calendar
Feb 11, 2016
Novartis AG at Leerink Partners Global Healthcare Conference - 3:30PM EST - Add to calendar
Jan 27, 2016
Q4 2015 Novartis AG Earnings Call
Jan 27, 2016
Q4 2015 Novartis AG Earnings Release
Jan 11, 2016
Novartis AG at JPMorgan Healthcare Conference
Dec 3, 2015
Novartis AG at Deutsche Bank dbAccess Pharmaceutical Corporate Day
Dec 2, 2015
Novartis AG at Berenberg European Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 8.23% 13.96%
Operating margin 13.10% 17.56%
EBITD margin - 30.24%
Return on average assets 3.20% 5.47%
Return on average equity 5.49% 9.49%
Employees 118,700 -
CDP Score - 94 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Company's segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Joseph Jimenez Jr Chief Executive Officer, Member of the Executive Committee
Age: 55
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 69
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 49
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Steven Baert Head Human Resources and Member of the Executive Committee
Age: 40
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters